23,461 Shares in Insulet Corporation $PODD Acquired by Meiji Yasuda Asset Management Co Ltd.

Meiji Yasuda Asset Management Co Ltd. acquired a new position in shares of Insulet Corporation (NASDAQ:PODD) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 23,461 shares of the medical instruments supplier’s stock, valued at approximately $3,572,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of PODD. Larson Financial Group LLC grew its holdings in Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. acquired a new position in shares of Insulet during the fourth quarter worth $26,000. DV Equities LLC purchased a new stake in shares of Insulet during the 4th quarter valued at $28,000. Elyxium Wealth LLC purchased a new stake in shares of Insulet during the 4th quarter valued at $28,000. Finally, Mcguire Capital Advisors Inc. acquired a new stake in shares of Insulet in the 4th quarter worth $29,000.

Insulet Trading Down 1.8%

NASDAQ:PODD opened at $145.42 on Tuesday. Insulet Corporation has a 12 month low of $126.40 and a 12 month high of $354.88. The firm has a fifty day simple moving average of $154.61 and a 200-day simple moving average of $183.56. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $10.08 billion, a P/E ratio of 27.18, a PEG ratio of 1.17 and a beta of 1.10.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The firm had revenue of $801.70 million for the quarter, compared to the consensus estimate of $787.39 million. During the same period in the prior year, the firm earned $1.17 EPS. The firm’s revenue was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, equities research analysts anticipate that Insulet Corporation will post 6.51 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Timothy C. Stonesifer purchased 2,790 shares of the company’s stock in a transaction on Wednesday, June 3rd. The shares were acquired at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the purchase, the director owned 9,041 shares in the company, valued at $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on PODD. Leerink Partners downgraded Insulet from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $247.00 to $145.00 in a research note on Thursday, August 6th. Sanford C. Bernstein decreased their price target on Insulet from $200.00 to $175.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Citigroup raised their price target on Insulet from $165.00 to $172.00 and gave the stock a “neutral” rating in a report on Wednesday, July 8th. Wells Fargo & Company downgraded Insulet from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $255.00 to $144.00 in a report on Wednesday, August 5th. Finally, Wall Street Zen lowered Insulet from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 9th. Fourteen analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $195.40.

Insulet News Roundup

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: CEO Ashley McEvoy purchased 1,100 Insulet shares at an average price of $147.47, an investment of approximately $162,200. The transaction increased her direct holdings by about 5% and may signal management confidence after the stock’s substantial decline. Insulet CEO share purchase article
• Neutral Sentiment: Multiple law firms—including Rosen, Bragar Eagel & Squire, Levi & Korsinsky, and others—are soliciting investors who purchased PODD securities during periods generally spanning February 21, 2025, through May 26, 2026. Investors have until August 31, 2026, to seek appointment as lead plaintiff. These announcements largely repeat existing litigation information rather than represent new operating developments. Rosen Law Firm Insulet deadline article
• Negative Sentiment: The lawsuit-related releases allege that Insulet and certain officers violated federal securities laws by failing to disclose issues associated with two voluntary Medical Device Corrections involving Omnipod insulin-delivery systems. The allegations reportedly concern systemic manufacturing defects and potential investor losses; they have not been proven in court. Continued legal publicity increases regulatory, financial, and reputational uncertainty for Insulet and is likely the main reason investor sentiment remains weak. Levi and Korsinsky Insulet class action article

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.